United States v. Little
United States v. Little
Opinion of the Court
*650At the end of an 18-day trial, a jury convicted Defendants Leon Little and Colise Harmon of conspiracy to distribute oxycodone and alprazolam, and related substantive offenses. Little moves for a judgment of acquittal or, in the alternative, a new trial, pursuant to Federal Rules of Criminal Procedure 29 and 33 with respect to all fifty counts on which he was convicted. Harmon moves for acquittal or a new trial with respect to the conspiracy count only. For the reasons that follow, the motions will be denied.
I. BACKGROUND
In November of 2011, agents from the Drug Enforcement Administration ("DEA") noticed a greater-than-60-fold increase since 2009 in orders of oxycodone products from a small drugstore in downtown Philadelphia, Philly Pharmacy.
Most of these cooperating witnesses had served as pseudo-patients, and many of them identified Defendant Little as the leader of the drug scheme and Defendant Harmon as a key player. Two of these witnesses, James Alexander and John Baldwin, admitted to recruiting additional patients to the scheme and acting as "drivers" by transporting patients and pills at Little's request. Alexander, Baldwin, and others identified Harmon as another driver who handled patients, pills, and money for the scheme. Among other witnesses, the Government also obtained testimony from *651Heather Herzstein, the receptionist at Dr. Browne's office who admitted to scheduling appointments for pseudo-patients in exchange for cash payments from Little; Brendin Strand, a Delaware-based drug dealer who admitted to purchasing and re-selling oxycodone pills from Little; and Aminah Shabazz, Little's romantic and business partner, who described multiple financial transactions she executed in support of the couple's plan to open a United Postal Service ("UPS") franchise using cash from the pill scheme.
Little and Harmon were first indicted by a federal grand jury on October 23, 2013 for conspiracy to distribute oxycodone and alprazolam, and related charges. The Third Superseding Indictment charged Little with one count of conspiracy to distribute oxycodone and alprazolam (a controlled anxiolytic substance sold under the brand name Xanax) between June 2010 and August 2012 in violation of
Defendants' jury trial began on November 29, 2016. Over the course of 13 days, the Government introduced testimony from more than two dozen witnesses, including Alexander, Baldwin, other pseudo-patients, Herzstein, Strand, Shabazz, relatives and friends of Shabazz who participated in the money laundering transactions, Little's ex-wife, the former owner of Northeast Pharmacy, an employee at a motorcycle dealer in Bensalem, Pennsylvania, a former vice president at the Sugar House Casino frequented by Little, agents from the DEA and Internal Revenue Service ("IRS"), and local law enforcement officers. The Government also presented more than 200 exhibits, including call logs and recordings, surveillance footage and pictures, GPS location data, prescription records, patient files, appointment books, sales records, records of financial transactions, and other documents. Both Defendants were represented by experienced counsel, who consistently challenged the credibility of the Government's witnesses during cross examination. On December 22, 2016, the jury returned a guilty verdict on all counts charged as to each Defendant.
Little filed a post-trial motion for acquittal, asserting that the evidence at trial was insufficient to support his conviction on any counts. Harmon filed a motion for acquittal or a new trial based on insufficiency of the evidence solely with respect *652to the conspiracy count. The Government responded to both motions, and Defendants were permitted to submit supplemental briefing. Little filed a supplemental motion for acquittal, and added a request for a new trial. Harmon also filed a supplemental motion limited to the conspiracy count. The Government responded to the supplemental motions, and Harmon filed a reply.
II. STANDARD OF REVIEW
A. Federal Rule of Criminal Procedure 29
A motion for judgment of acquittal under Rule 29 of the Federal Rules of Criminal Procedure may only be granted where the evidence is insufficient to sustain the conviction.
B. Federal Rule of Criminal Procedure 33
Under Federal Rule of Criminal Procedure 33, the trial court may grant a new trial when there is a finding of trial error or when the trial court does not believe that the evidence supports the jury's verdict. A motion for new trial pursuant to Rule 33 is directed to the sound discretion of the trial court.
III. DISCUSSION
A. Little's and Harmon's Convictions for Conspiracy to Distribute Oxycodone and Alprazolam (Count One)
Both Harmon and Little challenge the sufficiency of the Government's evidence supporting their convictions for conspiracy to distribute oxycodone and alprazolam. To establish a conspiracy in violation of
1. Sufficiency of Evidence Against Little
At trial, the Government presented extensive evidence to establish Little's participation in a conspiracy to obtain and distribute oxycodone and alprazolam for distribution. Patient and pharmacy records indicated that Little personally presented oxycodone prescriptions to pharmacies at least between August 2010 and April 2011.
In asserting that the evidence at trial was insufficient to support his conviction, Little contends that the cooperating Government witnesses-Strand, Herzstein, Alexander, Baldwin, and other pseudo-patients, whose testimony were essential for establishing Little's participation in the pill scheme-were not credible in light of contradictions in their statements, their history of untruthfulness, criminality, and drug addiction, and their motivation to implicate Little based on the potential sentencing incentives created by their cooperation agreements. Little further contends that the totality of the evidence at trial supports the existence of multiple independent conspiracies led by Herzstein, Alexander, and others, rather than a single conspiracy led by Little. Neither of these arguments supports a judgment of acquittal or a new trial.
At the outset, credibility is a determination that belongs to the jury, and the Court must presume "that the jury has properly carried out its functions of evaluating credibility of witnesses, finding the facts, and drawing justifiable inferences."
While Little asserts that "[a]ll of the government's cooperating witnesses proffered information to the government in an attempt to avoid potential draconian sentences," and a majority of these witnesses "violated the terms and conditions of their pre-trial release,"
Similarly, the specific contradictions and inconsistencies in testimony raised by Little do not warrant disturbing the jury verdict. Little relies heavily on the contradiction between patient records showing visits by Little and other pseudo-patients to Dr. Browne's office at its 111 Presidential Boulevard location and Herzstein's testimony that her arrangement with Little began only after Dr. Browne's office moved to 1 Bala Avenue in September 2010 and Dr. Browne's wife, not Herzstein, was responsible for scheduling any illegitimate patients at the prior location. Little contends that this inconsistency undermines Herzstein's testimony that Little, rather than she herself, directed and coordinated the influx of pseudo-patients to Dr. Browne's office. However, in light of other testimony and record evidence corroborating the existence of an agreement between Herzstein and Little as of July 2010, a jury could reasonably conclude that Herzstein misrepresented or simply misremembered the timing of her initial conversation with Little, while crediting her testimony regarding the substance of their agreement. Cell phone records introduced at trial established that Little and Herzstein first communicated by phone in July of 2010, and patient records from Dr. Browne's office indicate that Little and other pseudo-patients associated with the charged conspiracy began visiting Dr. Browne's office that month.
The other inconsistencies raised by Little similarly do not undermine the jury's verdict. Little contends that Herzstein's testimony concerning the financial terms of her agreement with Little is contradicted by her inability during cross examination to explain where the cash payments from Little went. But a jury could reasonably believe Herzstein's direct testimony that she used the money to pay off her car and other debts, and helped out her mother *656and her family.
As with Little's challenges to the credibility of cooperating witnesses, his arguments concerning the existence of multiple pill conspiracies were presented to, and rejected by, the jury at trial. During his opening statement, cross examinations, and closing argument, Little's counsel advanced his theory that Herzstein, Alexander, and other individuals organized multiple conspiracies that operated independently of Little.
At the close of trial, the jurors were specifically instructed that in order to reach a guilty verdict, they must find the existence of the single conspiracy charged in the indictment. The jury was also provided with the factors used to evaluate whether the evidence at trial supports the existence of a single conspiracy rather than multiple independent conspiracies:
In determining whether a series of events constitutes a single conspiracy or separate and unrelated conspiracies you should consider whether there was a common goal among the alleged conspirators and whether there existed common or similar methods, whether and to what extent alleged participants overlapped in their various dealings, whether and to what extent the activities of the alleged conspirators were related and interdependent, how helpful each alleged co-conspirator's contributions were to the goals of the others, and whether the *657scheme contemplated a continuing objective that would not be achieved without the ongoing cooperation of the conspirators.42
In evaluating whether there was a single conspiracy, the jury had testimony and other evidence that over the span of several years, dozens of pseudo-patients consistently obtained prescriptions from Dr. Browne's office and filled them at one or more of three pharmacies; that Little personally arranged with Herzstein to schedule appointments for these pseudo-patients; that the costs of the doctor's appointments and prescriptions, as well as the payments to Herzstein, the pseudo-patients, and their drivers, were all funded by Little; that the pills obtained by the pseudo-patients were collected and delivered to Little; and that Little sold pills obtained from the scheme to Strand and others in the presence of his drivers Alexander, Baldwin, and Harmon. This, among other evidence presented at trial, was sufficient for the jury to find that Little knowingly joined and participated in a single conspiracy to obtain and distribute oxycodone as charged in Count One.
In summary, the verdict must be upheld because a reasonable juror "could accept the evidence as sufficient to support the conclusion of the defendant's guilt beyond a reasonable doubt."
2. Sufficiency of Evidence Against Harmon
At trial, in addition to evidence discussed above concerning the existence of a conspiracy to obtain and distribute oxycodone and alprazolam for distribution, the Government introduced additional evidence to support Harmon's participation in the conspiracy. Patient and pharmacy records introduced at trial show that Harmon personally presented oxycodone prescriptions to pharmacies at least between August of 2010 and February of 2011.
In contesting the sufficiency of the evidence to support his conviction, Harmon relies primarily on three arguments. First, Harmon asserts that there is no direct evidence of communications between him and certain other members of the conspiracy during certain periods of time when he was alleged to have actively participated in the conspiracy. Specifically, Harmon alleges that the Government failed to present the following at trial: 1) direct testimony or records of any communications between Harmon and Little between April 2012 until the end of the conspiracy in August 2012, the period of time when Harmon was the primary driver for the pill scheme; 2) records of calls between Harmon and pseudo-patients before each of the appointments scheduled after April 2012; 3) records of any calls between Harmon and Alexander prior to March 3, 2011 or after Harmon's release from jail in December 2011, a period of time during which Alexander testified that he dropped off and picked up cash and pills from Harmon on numerous occasions; 4) records of calls between Harmon and John Baldwin at any time during the conspiracy; and 5) records of calls between Harmon and Strand at any time in the conspiracy.
The call logs presented by the DEA agent at trial did not purport to constitute a comprehensive set of all communications that took place among the conspirators, and the jury could reasonably rely on additional evidence of Harmon's interactions with others during the periods of time in question. Agent Lauriha testified that the Government only received telephone records for telephone numbers maintained by the telephone providers, and the Government was unable to obtain records for certain numbers.
Second, Harmon points to inconsistencies in the testimony of several cooperating witnesses concerning his role as a driver. In particular, Harmon asserts that Baheejah Alwan, McClain, Norton, and Herzstein all testified that Harmon had driven or otherwise interacted with them between March 4, 2011 and December 2011, a period of time during which he was incarcerated. However, a reasonable jury is entitled to credit the witnesses' testimony regarding interactions they had with Harmon while not crediting their testimony regarding the dates on which those interactions occurred. This is particularly reasonable given the several years that passed between the interactions at issue and the witnesses' testimony at trial. Moreover, neither Norton nor Herzstein testified that they interacted with Harmon specifically between March and December 2011. Rather, Norton testified that Alexander and Harmon alternated as his driver beginning in about January or February 2011, and Herzstein testified that Alexander and Harmon took over the role of paying her after Little stopped visiting the office as a pseudo-patient around March of 2011. Neither of these statements is directly incongruous with the timing of Harmon's incarceration.
None of the other contradictions asserted by Harmon undermines the reasonableness of the jury verdict:
• Although Herzstein's and Baldwin's testimony were inconsistent as to whether she received an $8,000 payment from Baldwin, and Herzstein's and Alexander's testimony were inconsistent as to whether they had brought their own pseudo-patients to Dr. Browne's office, both disputes are entirely collateral to the witnesses' testimony concerning Harmon's role in the conspiracy.
• Similarly, Edward Jones's failure during proffer sessions to truthfully identify his girlfriend as the person who recruited him to the pills scheme is not substantively pertinent to his trial testimony that Harmon drove him to doctor's appointments.
• Although McClain admitted during cross examination that he could not accurately recall when Alexander first began driving him to appointments, a reasonable jury could nonetheless credit McClain's testimony that Harmon drove him to appointments before Alexander did.
• While Coleman's grand jury testimony that Harmon was her first driver may be inconsistent with her testimony at trial that Baldwin was her first driver, the discrepancy can be explained by evidence that Harmon *660drove her to fill a set of forged prescriptions before Baldwin drove her to her first doctor's appointment.58
Overall, in light of the multiple witnesses who consistently testified that Harmon transported patients, drugs, and money in support of Leon Little's pill scheme, the specific contradictions raised by Harmon do not undermine the overall sufficiency of the evidence to establish Harmon's role in the conspiracy.
Third, Harmon contends that the Government failed to establish a unity of purpose or intent between Harmon and his conspirators because there was no evidence that Harmon reaped the same financial benefits as others in the conspiracy, including Little, Alexander, Herzstein, and Baldwin. However, the Government is not required to show parity in benefits in order to establish the existence of a common agreement and objective. Rather, as discussed above, there was ample evidence from trial from which a reasonable jury could conclude that Harmon and others joined and participated in a conspiracy with the common objective of acquiring and distributing controlled substances.
Accordingly, the Court concludes that sufficient evidence supports Harmon's conviction for conspiracy to distribute oxycodone and alprazolam, and there is no indication that his conviction was a miscarriage of justice warranting a new trial. Harmon's motion for acquittal or a new trial will be denied.
B. Little's Conviction for Distribution of Oxycodone (Counts 2-10, 16-30)
Little challenges his conviction for distribution of oxycodone in violation of
At trial, the Government introduced testimony and records from Northeast Pharmacy, Pharmacy of America, and Philly Pharmacy showing that prescriptions for oxycodone products were filled under Leon Little's name between August 2010 and April 2011 on each of the nine days alleged in Counts 2-10.
Little does not present specific arguments challenging the evidence supporting these offenses separate from the arguments presented with respect to his conspiracy conviction. Based on the record evidence of the prescriptions filled by Harmon and Little, and additional evidence that all pills acquired by members of Little's pill scheme were collected by Little for sale to customers, a reasonable jury could conclude Little knowingly distributed the oxycodone pills he obtained in his own name and aided and abetted Harmon in distributing the oxycodone pills obtained in his name. For these reasons, and for the reasons discussed with respect to Count One, Little's motion for acquittal and a new trial will be denied with respect to Counts 2-10 and 16-30.
C. Little's Conviction for Acquiring Oxycodone by Fraud (Counts 11-15, 31-34)
Little also challenges his conviction for acquiring oxycodone by fraud in violation of
At trial, Agent Lauriha testified that 10 of the oxycodone prescriptions filled by Little and 15 of the oxycodone prescriptions filled by Harmon were duplicates of other prescriptions filled at another pharmacy.
Apart from arguments raised with respect to Count One, Little's only argument regarding the acquisition-by-fraud counts is that the forged prescriptions were signed by Herzstein rather than Little. Specifically, Little relies on testimony from Coleman, Norton and Jones that they obtained signed duplicate prescriptions directly from Herzstein.
D. Little's Conviction for an Unlawful Monetary Transaction (Count 35)
Although Little's original motion states that he contests the sufficiency of the evidence with respect to each count for which he was convicted, his supplemental motion does not present any arguments directed to his conviction for money laundering in violation of
At trial, the Government presented video footage of Little, accompanied by others, *663purchasing a 2010 Can-Am Spyder, a three-wheeled motorcycle, from East Coast Cycle Center in Bensalem, Pennsylvania on March 18, 2011.
Based on this evidence, and evidence of his participation in the pill scheme, a reasonable jury could conclude that Little purchased the motorcycle using drug proceeds in violation of
E. Little's Conviction for Money Laundering (Counts 36-50)
Little contends that the record was insufficient to prove that he caused or aided and abetted the 15 money laundering transactions alleged in Counts 36-50. To establish money laundering in violation of
At trial, Shabazz testified that she and Little jointly planned to accumulate sufficient funds under the name of their jointly owned company, Lemin Consulting, in order to support the start of a UPS franchise, and that as part of that plan, she engaged in a series of financial transactions to move cash generated by Little's pill scheme into Lemin Consulting's account.
*664Bank showed that two checks for $9,000 each from Beneficial Bank and Citizen's Bank were deposited into an account for the Chasing Dreams Foundation on November 17, 2018. Shabazz also testified that after a Thanksgiving turkey drive that she organized with Little, she wrote two checks for $5,040 and $9,000 respectively to her stepmother on November 22, 2011.
With respect to Counts 40 and 49, Shabazz further testified that she gave cash that she received from Little to a former colleague and asked the colleague to deposit the cash into his Boeing Helicopter Credit Union Bank account and issue a cashier's check for $27,000 to Lemin Consulting.
With respect to Counts 41-44 and 46, Shabazz testified that she gave cash obtained from Little to her close friend and asked her to make four cash deposits totaling $40,000 on November 17, 2011 and November 18, 2011.
In asserting that the evidence at trial is insufficient to sustain his conviction, Little's only argument is that Shabazz's testimony lacks credibility. Specifically, Little contends that "Aminah Shabazz is a serial liar and obstructer of justice," and points to Shabazz's history of fraud and perjury and her motivation to falsely implicate Little under the terms of her cooperation agreement. However, as discussed with respect to Count One, the incentives created by cooperation agreements were addressed at length by the Government and Defense counsel throughout the trial, and the jury was specifically instructed regarding appropriate consideration of such in assessing the credibility of cooperating witnesses. Shabazz's history of fraud and dishonesty were also raised repeatedly during both direct and cross examination. The jury was thus well equipped to evaluate Shabazz's testimony.
Moreover, the existence of the monetary transactions at issue is well corroborated by documentary evidence and the testimony of other witnesses who participated in the transactions. Shabazz's testimony that the transactions were conducted with Little's money, and that Little's money came from illegal drug sales, was corroborated by evidence that she had limited access to other sources of income and Little had no *665other regular source of funds. Finally, to the extent Little challenges the credibility of Shabazz's testimony concerning Little's knowledge of the transactions, the jury could reasonably choose to believe Shabazz's potentially self-serving testimony that she and Little jointly planned these transactions as part of their long-term business goals rather than Little's similarly self-serving assertion that he was unaware of what Shabazz was doing with his money.
Accordingly, Little has failed to establish that the evidence at trial was insufficient to support his conviction for money laundering or that the conviction was otherwise against the weight of the evidence. Little's motion will be denied with respect to Counts 36-50.
IV. CONCLUSION
For the reasons discussed, the Court holds that the evidence presented at trial is sufficient to sustain Little and Harmon's convictions with respect to Count One and Little's conviction with respect to Counts Two through 50 of the Third Superseding Indictment. The Court also holds that the jury's verdict was not against the weight of the evidence, and that the interest of justice does not warrant a new trial. Defendants' motions pursuant to Federal Rules of Criminal Procedure 29 and 33 will therefore be denied.
An order follows.
November 30, 2018 Trial Testimony of Agent Jeffrey Lauriha (Doc. No. 371) at 112-13. Specifically, orders for oxycodone products increased from approximately 27,000 dosage units in 2009 to over 1.7 million dosage units in 2011.
The community is currently named the Raymond Rosen Manor.
Third Superseding Indictment (Doc. No. 211).
Jury Verdict Form (Doc. No. 304).
United States v. Gonzales ,
United States v. Wexler ,
United States v. Brodie ,
United States v. Wasserson ,
Boria ,
United States v. Mercado ,
United States v. Coleman ,
United States v. Rottschaefer,
United States v. Johnson ,
United States v. Davis ,
The parties stipulated that oxycodone and alprazolam are controlled substances.
See December 16, 2016 Testimony of Agent Lauriha (Doc. No. 383) at 195, 197-205.
December 2, 2016 Testimony of Heather Herzstein (Doc. No. 373) at 100, 117, 119, 122, 124-25.
Testimony of James Alexander (Doc. No. 374) at 156-57, 178-215; December 7, 2016 Testimony of John Baldwin (Doc. No. 376) at 9-10, 14-20, 23-25, 27-34.
December 13, 2016 Testimony of Frank Norton (Doc. No. 380) at 13-16; December 8, 2018 Testimony of Charles McLaurin (Doc. No. 377) at 191-93.
December 5, 2016 Testimony of Latoya Williams (Doc. No. 374) at 107-09; December 13, 2016 Testimony of Carla Trippett (Doc. No. 380) at 114-16.
December 8, 2016 Testimony of Brendin Strand (Doc. No. 377) at 44-48, 49-50, 87-88.
Alexander Testimony (Doc. No. 374) at 266-270; Baldwin Testimony (Doc. No. 376) at 48-58.
Coleman,
Little's Supplemental Motion (Doc. No. 404) at 1-2.
Id. at 2.
See, e.g., Closing Argument by Little (Doc. No. 385) at 145-46 ("You see...it's how the system is built, this whole idea of cooperation. It's like taking a carrot and putting it in front of a horse and leading them down a pathway. What's the horse going to do?"); Closing Argument by Harmon (Doc. No. 386) at 28 ("[R]emember folks, cooperation is like an ATM machine. Right? You put money in the bank. At the time of sentencing you take it out.").
Closing Jury Instructions (Doc. No. 386) at 76.
December 19, 2016 Testimony of Agent Lauriha (Doc. No. 384) at 17-18.
Herzstein Testimony (Doc. No. 373) at 111-14.
See, e.g. , Norton Testimony (Doc. No. 380) at 13-25; McLaurin Testimony (Doc. No. 377) at 225.
Herzstein Testimony (Doc. No. 373) at 210.
Baldwin Testimony (Doc. No. 376) at 105-06.
In support of his theory, Little also points to the fact that he, unlike the drivers and pseudo-patients, "was never observed by law enforcement" while "engaging in any activities relating to running a pill operation," interacting with pseudo-patients, or present at or near Dr. Browne's office or the target pharmacies. Little's Supp. Mot. (Doc. No. 404) at 11. However, as discussed above, Little's participation in the conspiracy was established through a substantial body of evidence other than direct surveillance, including the testimony of the pseudo-patients and drivers and call logs and recordings of Little's communications with co-conspirators and pseudo-patients. Moreover, Little's absence at Dr. Browne's office and Philly Pharmacy after the DEA began actively monitoring the locations is consistent with evidence that by late 2011, Little had ceased to act as a pseudo-patient himself and had delegated responsibility for the transportation of patients to his drivers.
Little's Supp. Mot. (Doc. No. 404) at 5.
See United States v. Rich,
Closing Jury Instructions (Doc. No. 386) at 100-01. See United States v. Kemp ,
Coleman ,
See Davis,
See Lauriha Testimony (Doc. No. 383) at 193-194, 206-211.
Herzstein Testimony (Doc. No. 373) at 118, 124-25.
Alexander Testimony (Doc. No. 374) at 218, 240, 263-64; Baldwin Testimony (Doc. No. 376) at 73.
December 7, 2012 Testimony of Kenshara Coleman (Doc. No. 376) at 196-200; Latoya Williams Testimony (Doc. No. 374) at 97-98.
Trippett Testimony (Doc. No. 380) at 107-08; Norton Testimony (Doc. No. 380) at 27-28; McClaurin Testimony (Doc. No. 377) at 200; December 12, 2016 Testimony of Marvin McClain (Doc. No. 379) at 86.
Norton Testimony (Doc. No. 380) at 54.
Strand Testimony (Doc. No. 377) at 44-48, 49-50, 87-88.
December 19, 2016 Testimony of Agent Lauriha (Doc. No. 384) at 35, 156-57.
Id. at 158-59.
Herzstein Testimony (Doc. No. 373) at 212; Strand Testimony (Doc. No. 377) at 90-91.
McClain Testimony (Doc. No. 379) at 86.
Id. at 61-62.
Alexander Testimony (Doc. No. 375) at 66-71.
Coleman Testimony (Doc. No. 376) at 204-11.
The additional testimony cited in Harmon's Reply also fails to raise any contradictions that undermine the verdict. Harmon's Reply (Doc. No. 423) at 1-2.
December 16, 2016 Testimony of Agent Lauriha (Doc. No. 383) at 195, 197-205.
December 13, 2016 Stipulation (Doc. No. 380) at 233-34.
Lauriha Testimony (Doc. No. 383) at 206-11.
Lauriha Testimony (Doc. No. 372) at 56-59.
Herzstein Testimony (Doc. No. 373) at 133-34, 173-74.
Alexander Testimony (Doc. No. 374) at 220; Baldwin Testimony (Doc. No. 376) at 36-37.
Norton Testimony (Doc. No. 380) at 34-35; December 9, 2016 Testimony of Edward Jones (Doc. No. 378) at 244-45; Coleman Testimony (Doc. No. 376) at 250-53.
The interstate commerce element of § 1957 requires only a minimal effect on interstate commerce, and Courts have held that the transfer of funds drawn from a federal-insured financial institution satisfies this requirement. United States v. Howard, No. 99-120,
Baldwin Testimony (Doc. No. 376) at 82-84.
December 13, 2018 Testimony of William Mack (Doc. No. 380) at 250-51.
Baldwin Testimony (Doc. No. 376) at 80-82, 86.
December 14, 2016 Testimony of Aminah Shabazz (Doc. No. 381) at 135-139, 168-173.
Shabazz Testimony (Doc. No. 381) at 174-77.
December 14, 2016 Testimony of D. Murphy (Doc. No. 381) at 25-35.
Shabazz Testimony (Doc. No. 381) at 187-90.
S. Anderson Testimony (Doc. No. 381) at 65-67.
Reference
- Full Case Name
- United States v. Leon LITTLE, United States of America v. Colise Harmon
- Status
- Published